Details
Imbruvica Indications
-
The Imbruvica is used to treat mantle-cell lymphoma in adult patients with relapsing or no response to previous treatment.
-
Imbruvica monotherapy is used to treat chronic lymphocytic leukemia in adult patients who have not received treatment before.
-
The Imbruvica is used to treat chronic lymphocytic leukemia in adult patients who have received at least one course of treatment.
-
The Imbruvica is used to treat Waldenstrem's macroglobulinemia in adult patients who have received at least one course of treatment, or as a first-line therapy in patients who can not receive chemo-immunotherapy.
-
IMBRUVICA® blocks a specific protein in B cells called Bruton’s tyrosine kinase, or BTK. BTK signaling is needed for abnormal B cells to multiply and survive1
-
By blocking BTK, IMBRUVICA® may help move abnormal B cells out of their nourishing environments in the lymph nodes, bone marrow, and other organs1,2
-
It’s important that you take IMBRUVICA® every day as prescribed by your doctor to manage your disease1
-
IMBRUVICA® may slow the spread of CLL or SLL1,3
Contradictions
Hypersensitivity to active or any of the excipients.
Simultaneous application with medicinal products containing extract of St. John's wort.
Dosage & Administration
The use of this product and the monitoring of its use should only be initiated by a doctor experienced in the use of anti-neoplastic drugs.
